TBI identification and monitoring through retinal scanning

项目总结/摘要 Rebion已经生产了一种便携式设备-在NS 117553的支持下-显示出作为 可以识别TBI导致的功能障碍的工具。该设备使用视网膜扫描来测量 视网膜和大脑视觉通路之间的中断。这项工作的长远目标是 开发一种工具，可以在受伤时以及在受伤期间对受伤进行功能评估。 恢复，并与目前可用的血液生物标志物配对，以提供全面的报告 为患者和供应商。该设备的方法，不像眼睛跟踪或任何其他可用的眼睛技术， 来评估视网膜和大脑之间的信号质量。准确监控功能和整体 从TBI中恢复是Rebion正在寻求帮助解决的医疗保健系统中服务不足的问题。 TBI（创伤性脑损伤）是年龄以下个体长期残疾和死亡的主要原因。 为45.在美国，每年报告超过250万例TBI病例，约有3-5百万人 与TBI相关的残疾。大约75%的TBI患者被归类为mTBI， 很难诊断，因为病史往往不完整，症状是非特异性的，与广泛的症状重叠。 一系列神经精神疾病虽然大多数mTBI患者完全康复，但仍有20%的患者 不要。这些是Rebion最终致力于帮助的患者。个人经历 多发性mTBI的持续性损伤后症状和长期并发症的风险增加，包括 严重后遗症如慢性创伤性脑病（CTE）。简单的干预措施，如删除 来自危险环境的患者可以通过让大脑有时间愈合来预防这些并发症， 防止进一步伤害。 正在申请拨款支持一项人类受试者研究，该研究将把Rebion设备与一种 一系列临床测试-血液生物标志物和神经认知评估-在疑似TBI的参与者中。 迄今为止收集的试点数据显示，这种快速、非侵入性的方法有望在以下方面发挥作用： 病人的创伤性脑损伤之旅

Project Summary/Abstract Rebion has produced a portable device – with support from NS117553 – that shows potential for serving as a tool that can identify functional impairment as a result of TBI. The device uses a retinal scan to measure disruptions between the retina and the visual pathway of the brain. The long-term vision of this work is to develop a tool that can serve as a functional assessment of injury at the time of injury, as well as during recovery, and to be paired with currently-available blood-based biomarkers to provide a comprehensive report for patients and providers. The device’s approach, unlike eye-tracking or any other available eye technology, is to assess the quality of signals between the retina and the brain. Accurate monitoring of function and overall recovery from TBI are underserved problems in the healthcare system that Rebion is seeking to help solve. TBI (traumatic brain injury) is the leading cause of long-term disability and death for individuals under the age of 45. Over 2.5 million cases of TBI are reported each year in the United States, with ~3-5 million individuals living with TBI-related disabilities. About 75% of patients diagnosed with TBI are classified as mTBI, which can be difficult to diagnose, as history is often incomplete and symptoms are nonspecific and overlap with a broad range of neuropsychiatric disorders. Although most patients with mTBI make a full recovery, as many as 20% do not. These are the patients that Rebion is ultimately focused on helping. Individuals who experience multiple mTBI are at increased risk of persistent post-injury symptoms and long-term complications, including serious sequelae such as chronic traumatic encephalopathy (CTE). Simple interventions such as removing the patient from risky environments may prevent these complications by allowing time for the brain to heal and preventing further injury. Grant support is being requested to support a human-subject study which will compare the Rebion device to a battery of clinical tests – blood biomarkers and neurocognitive assessments – in participants suspected of TBI. Pilot data collected to-date shows promise that this rapid, non-invasive method can serve a useful purpose in the patient’s journey through TBI.